CERo Therapeutics Reports Positive Phase 1 Clinical Update for AML/MDS Drug CER-1236
CERO is trading near its 52-week low of $0.05 (10% above the low) on light trading volume (0.2× avg).
Summary
CERo Therapeutics announced positive safety data and an observed platelet transfusion-free interval in a patient during its Phase 1 trial of CER-1236 for AML and Myelodysplastic Syndrome.
Key Events · Product Development and Regulatory · CERO
-
Positive Phase 1 Clinical Update
The company provided a clinical update on its Phase 1 trial (CertainT-1) for CER-1236 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
-
Key Safety Data Highlighted
The update highlighted positive key safety data for the investigational drug CER-1236.
-
Early Efficacy Signal Observed
A platelet transfusion-free interval was observed in a patient with Myelodysplastic Syndrome/AML, indicating a potential early efficacy signal.
Analysis · CERO · Life Sciences
This filing, incorporating an 8-K, provides a positive clinical update on CERo Therapeutics' Phase 1 trial for CER-1236 in AML and Myelodysplastic Syndrome. For a micro-cap life sciences company, positive safety data and an early efficacy signal, such as a platelet transfusion-free interval in a patient, are critical de-risking events. This progress in a clinical trial can significantly impact investor confidence and the company's valuation, as it moves closer to demonstrating the drug's potential.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CERO was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.05 to $410,000.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.